title: Molecularly targeted therapy: when to stop and when to continue?
authors.forename: Fred R
authors.initials: FR
authors.lastname: Hirsch
authors.forename: Tony S
authors.initials: TS
authors.lastname: Mok
authors.forename: Virginia
authors.initials: V
authors.lastname: Borges
authors.forename: Paul A
authors.initials: PA
authors.lastname: Bunn
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D016903:Drug Monitoring; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human